Stančiaková Lucia, Brisudová Kristína, Škorňová Ingrid, Bolek Tomáš, Samoš Matej, Biringer Kamil, Staško Ján, Sokol Juraj
National Center of Hemostasis and Thrombosis, Department of Hematology and Transfusion Medicine, Martin University Hospital, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 01 Martin, Slovakia.
Department of Internal Medicine I., Martin University Hospital, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 01 Martin, Slovakia.
Pharmaceuticals (Basel). 2024 Jun 13;17(6):773. doi: 10.3390/ph17060773.
Venous thromboembolism (VTE) represents one of the leading causes of death during pregnancy. The greatest risk for it is the presence of medical or family history of VTE, stillbirth, cesarean section and selected thrombophilia. Appropriate thromboprophylaxis has the potential to decrease the risk of VTE in at-risk pregnant patients by 60-70%. Based on this, the authors reviewed the PubMed, Web of Science and Scopus databases to identify the possibilities of thromboprophylaxis in pregnant patients with a high risk of VTE. Moreover, they summarized its management in specific situations, such as cesarean delivery or neuraxial blockade. Currently, low-molecular-weight heparins (LMWH) are the preferred drugs for anticoagulant thromboprophylaxis in the course of pregnancy and postpartum due to easy administration and a lower rate of adverse events.
静脉血栓栓塞症（VTE）是孕期主要死因之一。其最大风险因素包括VTE病史或家族史、死产、剖宫产以及特定的易栓症。适当的血栓预防措施有可能将高危孕妇发生VTE的风险降低60%至70%。基于此，作者检索了PubMed、科学网和Scopus数据库，以确定对VTE高危孕妇进行血栓预防的可能性。此外，他们总结了在剖宫产或神经阻滞等特定情况下的处理方法。目前，低分子量肝素（LMWH）因其易于给药且不良事件发生率较低，是孕期及产后抗凝血栓预防的首选药物。
